Cite
MLA Citation
Rahul Aggarwal et al.. “341 Phase 1b/2 study of BXCL701, an oral activator of the systemic innate immunity pathway, combined with pembrolizumab (pembro), in men with metastatic castration-resistant prostate cancer (mCRPC).” Journal for immunotherapy of cancer, vol. 8, n.d., p. A366. http://access.bl.uk/ark:/81055/vdc_100144713769.0x000004